.jpg)
Metastatic NSCLC: Why and How to Standardize Biomarker Testing
This study demonstrated that implementing a standardized approach to biomarker testing, including provider education, EHR templates, and order sets, increased comprehensive biomarker testing rates in a community oncology practice setting.
Time Toxicity in NSCLC: Understanding Healthcare Contact Days for Patients
Investigators found that patients with stage IV non鈥搒mall cell lung cancer spend, on average, approximately 30% of their 3.5 months of survival time with healthcare contact outside of the home.
Predicting NSCLC Outcomes: The Role of Body Composition Metrics
Automated extraction of body composition parameters from computed tomography images, using deep learning, showed that loss of skeletal muscle mass was associated with worse outcomes in patients being treated with systemic therapy for advanced NSCLC.
Exon 20 Insertion in NSCLC: How Do Patients Fare?
Using ASCO data, investigators assessed patient characteristics, treatment patterns, and outcomes among patients with EGFR exon 20-mutated non-small cell lung cancer.